Trial Profile
A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Assess the Safety, Pharmacokinetics, Efficacy and Pharmacodynamics of KBSA301 in Severe Pneumonia (S. Aureus)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Tosatoxumab (Primary)
- Indications Methicillin-resistant Staphylococcus aureus infections; Pneumonia; Staphylococcal infections
- Focus First in man; Therapeutic Use
- Sponsors Aridis Pharmaceuticals
- 07 Nov 2018 According to an Aridis Pharmaceuticals media release, data from this trial was presented at the 31st Annual Congress of the European Society of Intensive Care Medicine and was published in the October 21, 2018 issue of the Intensive Care Medicine journal.
- 05 Jun 2017 According to an Aridis Pharmaceuticals media release, top-line results from the study have been presented at the 2017 ASM Microbe congress.
- 25 Apr 2017 Results presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases